Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Edelman, Martin, M.D. Bristol-Myers Squibb |
---|---|
Information provided by: | Edelman, Martin, M.D. |
ClinicalTrials.gov Identifier: | NCT00037089 |
This study is for patients with esophageal cancer that has spread to other areas. The purpose of this study is to:
Condition | Intervention | Phase |
---|---|---|
Esophageal Neoplasm |
Drug: UFT (Tegafur/Uracil) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Ages Eligible for Study: | 18 Years to 79 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
INCLUSION
EXCLUSION
Study ID Numbers: | BMS-200604, UMCC 0110g |
Study First Received: | May 14, 2002 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00037089 |
Health Authority: | United States: Food and Drug Administration |
Digestive System Neoplasms Digestive System Diseases Esophageal disorder Tegafur Paclitaxel Gastrointestinal Diseases |
Head and Neck Neoplasms Esophageal Neoplasms Leucovorin Gastrointestinal Neoplasms Esophageal Diseases Esophageal neoplasm |
Neoplasms Neoplasms by Site |